IL324338A - טיפול במצבי היפרפיגמנטציה באמצעות רעלן בוטולינום - Google Patents

טיפול במצבי היפרפיגמנטציה באמצעות רעלן בוטולינום

Info

Publication number
IL324338A
IL324338A IL324338A IL32433825A IL324338A IL 324338 A IL324338 A IL 324338A IL 324338 A IL324338 A IL 324338A IL 32433825 A IL32433825 A IL 32433825A IL 324338 A IL324338 A IL 324338A
Authority
IL
Israel
Prior art keywords
botulinum toxin
injection site
injection
per injection
dose
Prior art date
Application number
IL324338A
Other languages
English (en)
Inventor
Kay Marquardt
Thomas Hengl
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Kay Marquardt
Thomas Hengl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa, Kay Marquardt, Thomas Hengl filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IL324338A publication Critical patent/IL324338A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
IL324338A 2023-07-12 2025-10-30 טיפול במצבי היפרפיגמנטציה באמצעות רעלן בוטולינום IL324338A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23185114 2023-07-12
PCT/EP2024/069733 WO2025012403A1 (en) 2023-07-12 2024-07-11 Treatment of hyperpigmentation conditions by botulinum toxin

Publications (1)

Publication Number Publication Date
IL324338A true IL324338A (he) 2025-12-01

Family

ID=87280519

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324338A IL324338A (he) 2023-07-12 2025-10-30 טיפול במצבי היפרפיגמנטציה באמצעות רעלן בוטולינום

Country Status (7)

Country Link
EP (1) EP4743107A1 (he)
KR (1) KR20260035809A (he)
CN (1) CN121511091A (he)
AU (1) AU2024288687A1 (he)
IL (1) IL324338A (he)
MX (1) MX2025013627A (he)
WO (1) WO2025012403A1 (he)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
KR100852824B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101640694B1 (ko) 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법
JP6608357B2 (ja) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
WO2018222652A1 (en) 2017-05-31 2018-12-06 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Also Published As

Publication number Publication date
AU2024288687A1 (en) 2025-10-23
EP4743107A1 (en) 2026-05-20
CN121511091A (zh) 2026-02-10
WO2025012403A1 (en) 2025-01-16
KR20260035809A (ko) 2026-03-13
MX2025013627A (es) 2025-12-01

Similar Documents

Publication Publication Date Title
US20070178121A1 (en) Methods for enhancing skin treatments
JP4138651B2 (ja) にきび治療または防止のためのボツリヌス毒素
US10245305B2 (en) Botulinum toxin therapy for skin disorders
Zhao et al. Comparing the efficacy of Myjet‐assisted tranexamic acid and vitamin C in treating melasma: A split‐face controlled trial
US20210162027A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
Kołodziejczak et al. The eye area as the most difficult area of activity for esthetic treatment
Kuster Kaminski Arida et al. Randomized, double‐blind, placebo‐controlled split‐face trial of the efficacy of tranexamic acid by drug delivery through microneedling in the treatment of melasma
US8530410B2 (en) Method for treating a keloid with a botulinum toxin
AU2024288687A1 (en) Treatment of hyperpigmentation conditions by botulinum toxin
US20180207087A1 (en) Kit and aesthetic system for prevention of skin aging
Sultan et al. Efficacy of intradermal tranexamic acid in melasma
Alzayadneh et al. Streamlined Facial Rejuvenation: A Randomized Split-Face Trial of Premixed Intradermal Botulinum Toxin Type A and Hyaluronic Acid Biorevitalization
RU2843280C1 (ru) Способ комплексного омоложения кожи периорбитальной области
KR20210008392A (ko) 국소 제제로부터의 생물학적 작용제의 전달 방법
US20250064708A1 (en) Use of botulinum toxin for reduction of skin pore size and sebum production
Naheed et al. Efficacy of Intradermal Transaxamic Acid in the Treatment of Melasma: A Retrospective Study of Clinical Cases
Park et al. Clinical Validation of Nanoscale Biophysical Modulation for Enhanced Transdermal Delivery (TDD): A Comparative Study Using a biomimetic Micro-Vacuum Patch for Advanced Peptide Penetration
WO2026053109A1 (en) Methods for enhancing transdermal delivery of botulinum toxins
Park et al. Enhanced Periorbital Tissue Remodeling through Sequential Collagenase and Radiofrequency Treatment: A Quantitative Nanoscale Analysis in a Rabbit Model
Schiappapietra-Gerez et al. Botulinum toxin for periorbital hidrocystomas in a referral center in Mexico City
Echague 19 High Frequency Ultrasound Evaluation of Cellulite Treated with the 1064 nm Nd: YAG Laser Régine Bousquet-Rouaud, Marie Bazan, Jean Chaintreuil, and